Anti-epileptic Drugs for Pediatrics have become far more efficient with fewer side-effects and more effective results

 

Anti-epileptic drugs for pediatrics are a diverse collection of anticonvulsant drugs used for the symptomatic treatment of seizure disorders. The names of the drugs come from their chemical makeup. They are commonly known as anti-epileptics or antipsychotic drugs. Anti-epileptics are also being utilized in the therapy of diabetic neuropathy since many seem to act like neuropathic pain suppressants, and for the symptomatic treatment of epilepsy, as many appear to be anticonvulsant.

One family of antiepileptic drugs is Carbamazepine, which acts on two types of brain cells - Basal cell (Sertraline) and Delayed Cell Death (DCD). It works by blocking a receptor that prevents sodium channels from being open to the nerve impulses that can travel to the synapses. It has few side effects and is generally effective in epileptic patients with mild or moderate cases. For treatment in children, it has been found to be efficacious and safe. However, it tends to reduce performance in patients with abnormal sodium channel function, such as with Parkinson's disease.

Anti-epileptic drugs for pediatrics stop the action of acetylcholine and other neurotransmitters. They have both anticonvulsant and sedative effects. They work by preventing the release of certain chemicals, such as dopamine and serotonin that stimulate the release of certain nerve cells responsible for experiencing epileptic seizures. When given with food, some drugs increase the amount of food eaten by the patient, allowing him to retain sufficient amounts of nutrients that are vital for normal cell functioning. Different types of drugs are available for this condition, depending on the type of seizure and the affected site. Generalized or Systemic Drugs are given to treat generalized seizures that cause loss of consciousness and slurred speech, which are accompanied by muscle twitching. Recently, Eisai Co., Ltd., a Japanese pharmaceutical company, launched a new fine granule formulation of its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel hydrate).